Exosomes Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Domain

DelveInsight's 'Exosomes Pipeline Insight 2026' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Exosomes pipeline landscape.

Apr. 1, 2026 at 9:48pm

Got story updates? Submit your updates here. ›

DelveInsight's 'Exosomes Pipeline Insight 2026' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Why it matters

The Exosomes Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Exosomes Pipeline Report also highlights the unmet needs with respect to the Exosomes.

The details

DelveInsight's 'Exosomes Pipeline Insight 2026' report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exosomes treatment. The leading Exosomes Companies such as Celularity, EVerZom, Direct Biologics, Cambium Bio, Capricor Therapeutics, Aegle Therapeutics, Organicell, Evecxia, ArunaBio, Evox, Coya Therapeutics, ILIAS Biologics, EV Therapeutics, Nano24, and others are involved in the development of promising Exosomes Therapies such as Olmutinib, Zofin, AGLE-102, and others.

  • On March 23, 2026- Direct Biologics LLC initiated a Phase III, multicenter, randomized, double-blinded, placebo-controlled trial for the treatment of moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).

The players

Direct Biologics LLC

A company that initiated a Phase III, multicenter, randomized, double-blinded, placebo-controlled trial for the treatment of moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) using its product ExoFlo, an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product.

Nano24

A company developing EXO-CD24, an investigational drug that is a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). EXO-CD24 is being developed as a targeted therapy for hyperimmune activation in the context of COVID-19.

Got photos? Submit your photos here. ›

The takeaway

The Exosomes Pipeline Report provides insights into the robust pipeline of Exosomes therapies, with over 80 active players working on more than 100 pipeline drugs. The report highlights the leading companies and promising therapies in this domain, as well as the unmet needs and future perspectives for the Exosomes market.